ClueBot NG Report Interface

// Viewing 1825060

Navigation

ID: 1825060
User: 109.153.238.105
Article: Bisphosphonate
Diff:
(Pharmacokinetics)
(Common)
Line 26: Line 26:
   
 
Recent studies have reported bisphosphonate use (specifically [[zoledronate]] and [[alendronate]]) as a risk factor for [[atrial fibrillation]] in women.<ref name="HORIZON">{{cite journal |author=Black DM, Delmas PD, Eastell R, et al. |title=Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis |journal=N. Engl. J. Med. |volume=356 |issue=18 |pages=1809–22 |date=May 2007 |pmid=17476007 |doi=10.1056/NEJMoa067312 |url=http://www.nejm.org/doi/full/10.1056/NEJMoa067312}}</ref><ref name="ArchIntMed2008">{{cite journal |author=Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM |title=Use of alendronate and risk of incident atrial fibrillation in women |journal=Arch. Intern. Med. |volume=168 |issue=8 |pages=826–31 |date=April 2008 |pmid=18443257 |doi=10.1001/archinte.168.8.826 |url=http://archinte.ama-assn.org/cgi/content/full/168/8/826}}</ref><ref name="FractureInterventionTrial">{{cite journal |author=Cummings SR, Schwartz AV, Black DM |title=Alendronate and atrial fibrillation |journal=N. Engl. J. Med. |volume=356 |issue=18 |pages=1895–6 |date=May 2007 |pmid=17476024 |doi=10.1056/NEJMc076132 }}</ref> The inflammatory response to bisphosphonates or fluctuations in [[calcium]] blood levels have been suggested as possible mechanisms.<ref name="ArchIntMed2008"/> One study estimated that 3% of atrial fibrillation cases might have been due to alendronate use.<ref name="ArchIntMed2008"/> Until now, however, the benefits of bisphosphonates, in general, outweigh this risk, although care must be taken in certain populations at high risk of serious adverse effects from atrial fibrillation (such as patients with [[heart failure]], [[coronary artery disease]], or [[diabetes]]).<ref name="ArchIntMed2008"/> FDA has not yet confirmed a causal relationship between bisphosphonates and atrial fibrillation.<ref>{{cite web|url=http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm070303.htm |title=Early Communication of an Ongoing Safety Review on Bisphosphonates: Alendronate (Fosamax, Fosamax Plus D), Etidronate (Didronel), Ibandronate (Boniva), Pamidronate (Aredia), Risedronate (Actonel, Actonel W/Calcium), Tiludronate (Skelid), and Zoledronic acid (Reclast, Zometa) |accessdate=2009-07-15 |date=2007-10-01 |work=Postmarket Drug Safety Information for Patients and Providers |publisher=[[Food and Drug Administration (United States)]] }}</ref><ref>{{cite web|url=http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm070303.htm |title=Update of Safety Review Follow-up to the October 1, 2007 Early Communication about the Ongoing Safety Review of Bisphosphonates |accessdate=2009-07-15 |date = October 2008|work=Postmarket Drug Safety Information for Patients and Providers |publisher=[[Food and Drug Administration (United States)]] }}</ref>
 
Recent studies have reported bisphosphonate use (specifically [[zoledronate]] and [[alendronate]]) as a risk factor for [[atrial fibrillation]] in women.<ref name="HORIZON">{{cite journal |author=Black DM, Delmas PD, Eastell R, et al. |title=Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis |journal=N. Engl. J. Med. |volume=356 |issue=18 |pages=1809–22 |date=May 2007 |pmid=17476007 |doi=10.1056/NEJMoa067312 |url=http://www.nejm.org/doi/full/10.1056/NEJMoa067312}}</ref><ref name="ArchIntMed2008">{{cite journal |author=Heckbert SR, Li G, Cummings SR, Smith NL, Psaty BM |title=Use of alendronate and risk of incident atrial fibrillation in women |journal=Arch. Intern. Med. |volume=168 |issue=8 |pages=826–31 |date=April 2008 |pmid=18443257 |doi=10.1001/archinte.168.8.826 |url=http://archinte.ama-assn.org/cgi/content/full/168/8/826}}</ref><ref name="FractureInterventionTrial">{{cite journal |author=Cummings SR, Schwartz AV, Black DM |title=Alendronate and atrial fibrillation |journal=N. Engl. J. Med. |volume=356 |issue=18 |pages=1895–6 |date=May 2007 |pmid=17476024 |doi=10.1056/NEJMc076132 }}</ref> The inflammatory response to bisphosphonates or fluctuations in [[calcium]] blood levels have been suggested as possible mechanisms.<ref name="ArchIntMed2008"/> One study estimated that 3% of atrial fibrillation cases might have been due to alendronate use.<ref name="ArchIntMed2008"/> Until now, however, the benefits of bisphosphonates, in general, outweigh this risk, although care must be taken in certain populations at high risk of serious adverse effects from atrial fibrillation (such as patients with [[heart failure]], [[coronary artery disease]], or [[diabetes]]).<ref name="ArchIntMed2008"/> FDA has not yet confirmed a causal relationship between bisphosphonates and atrial fibrillation.<ref>{{cite web|url=http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm070303.htm |title=Early Communication of an Ongoing Safety Review on Bisphosphonates: Alendronate (Fosamax, Fosamax Plus D), Etidronate (Didronel), Ibandronate (Boniva), Pamidronate (Aredia), Risedronate (Actonel, Actonel W/Calcium), Tiludronate (Skelid), and Zoledronic acid (Reclast, Zometa) |accessdate=2009-07-15 |date=2007-10-01 |work=Postmarket Drug Safety Information for Patients and Providers |publisher=[[Food and Drug Administration (United States)]] }}</ref><ref>{{cite web|url=http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm070303.htm |title=Update of Safety Review Follow-up to the October 1, 2007 Early Communication about the Ongoing Safety Review of Bisphosphonates |accessdate=2009-07-15 |date = October 2008|work=Postmarket Drug Safety Information for Patients and Providers |publisher=[[Food and Drug Administration (United States)]] }}</ref>
  +
  +
The use of bisphosphonate drugs prevent the rebuilding of bone. So they are not a suitable drug to take if you have osteoporosis.
   
 
===Long-term risks===
 
===Long-term risks===
Reason: ANN scored at 0.857936
Reporter Information
Reporter: Bradley (anonymous)
Date: Thursday, the 22nd of October 2015 at 05:54:13 PM
Status: Reported
Wednesday, the 7th of May 2014 at 08:08:58 AM #94439
Anonymous (anonymous)

Wake up Wikipedia!!! Time to put some useful and correct info on your site.

Thursday, the 22nd of October 2015 at 05:54:13 PM #101889
Bradley (anonymous)

XMSBQb http://www.FyLitCl7Pf7kjQdDUOLQOuaxTXbj5iNG.com

Username:
Comment: